Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 1999
Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussisB Trollfors, J Taranger, T Lagergård, et al.Developments in Biological Standardization|December 17, 1998
Standardization may suffice for licensure of conjugate vaccinesJ B Robbins, R Schneerson, S C Szu, et al.The Journal of Pediatrics|April 1, 1997
Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussisB Trollfors, J Taranger, T Lagergård, et al.The Journal of Infectious Diseases|February 18, 1998
Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adultsE Y Konadu, J C Parke, H T Tran, et al.The Pediatric Infectious Disease Journal|February 1, 1997
Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infantsJ Taranger, B Trollfors, T Lagergård, et al.Infection and Immunity|March 18, 2000
Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in miceD Pavliakova, J S Moncrief, D M Lyerly, et al.Journal of the American Society of Nephrology : JASN|February 1, 1996
Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysisP G Welch, A Fattom, J Moore, et al.Pediatrics|June 1, 1991
Intelligence at six years in relation to neonatal bilirubin levels: follow-up of the National Institute of Child Health and Human Development Clinical Trial of PhototherapyP C Scheidt, B I Graubard, K B Nelson, et al.Infection and Immunity|September 25, 1999
Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in miceD Pavliakova, C Chu, S Bystricky, et al.Infection and Immunity|October 1, 1994
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccinesS C Szu, D N Taylor, A C Trofa, et al.Pageof 3